Market research
ENTX Entera Bio Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 559M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- Not available
- Beta
- 1.4
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011429839
- Market cap
- 559M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- Not available
- Beta
- 1.4
About
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ENTX discussion.
5 years, 4 months ago
Entera Bio Ltd is currently in a long term uptrend where the price is trading 137.2% above its 200 day moving average.
From a valuation standpoint, the stock is 86.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 176.0.
Entera Bio Ltd's total revenue rose by 116.7% to $221K since the same quarter in the previous year.
Its net income has increased by 34.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 57.0% to $-1M since the same quarter in the previous year.
Based on the above factors, Entera Bio Ltd gets an overall score of 5/5.